SCHEMBL7224360

SCHEMBL7224360

N=C(N)c1c[nH]c2ccc(CCNC(=O)c3ccc(-c4ccc(=O)[nH]c4)cc3)cc12

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
CDK4 P11802 5/20 0.44
CCND1 P24385 5/20 0.44
LMNA P02545 2/20 0.44
SNCA P37840 5/20 0.43
TRPV1 Q8NER1 1/20 0.43
F10 P00742 1/20 0.42
MCHR1 Q99705 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7224324 0.90 CDK4 (0.47) KMT2AL3MBTL1CDK4CCND1LMNA
SCHEMBL7222768 0.90 LMNA (0.45) KMT2AMEN1L3MBTL1LMNAPOLB
SCHEMBL7851834 0.89 SNCA (0.43) L3MBTL1CDK4CCND1LMNASNCA
SCHEMBL7222504 0.89 MEN1 (0.46) KMT2AMEN1L3MBTL1LMNASNCA
SCHEMBL7225358 0.87 SNCA (0.52) CDK4CCND1SNCATRPV1F10
SCHEMBL7231033 0.86 SNCA (0.45) L3MBTL1CDK4CCND1LMNASNCA
SCHEMBL7230763 0.86 SMN1; SMN2 (0.41) KMT2AMEN1L3MBTL1CDK4CCND1
SCHEMBL7224750 0.86 KMT2A (0.58) KMT2AMEN1L3MBTL1CDK4CCND1
SCHEMBL7224921 0.86 CDK4 (0.44) KMT2AMEN1L3MBTL1CDK4CCND1
SCHEMBL7222947 0.85 SNCA (0.60) KMT2AMEN1SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US claimed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US claimed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP claimed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO claimed
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 KMT2A 1746/4885MEN1 826/4885L3MBTL1 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.